Cargando…

An enhanced genetic mutation-based model for predicting the efficacy of immune checkpoint inhibitors in patients with melanoma

BACKGROUND: Programmed death ligand 1 (PD-L1) and tumor mutation burden (TMB) have been developed as biomarkers for the treatment of immune checkpoint inhibitors (ICIs). However, some patients who are TMB-high or PD-L1-high remained resistant to ICIs therapy. Therefore, a more clinically applicable...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pan, Chaohu, Tang, Hongzhen, Wang, Wei, Wu, Dongfang, Luo, Haitao, Xu, Libin, Lin, Xue-Jia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9887306/ https://www.ncbi.nlm.nih.gov/pubmed/36733353 http://dx.doi.org/10.3389/fonc.2022.1077477

Ejemplares similares

Systematic assessment and optimizing algorithm of tumor mutational burden calculation and their implications in clinical decision-making
por: Sun, Daqiang, et al.
Publicado: (2022)

Biomarkers for Immune Checkpoint Inhibitors in Melanoma
por: Kitano, Shigehisa, et al.
Publicado: (2018)

De Novo Mutation in Non-Tyrosine Kinase Domain of ROS1 as a Potential Predictor of Immune Checkpoint Inhibitors in Melanoma
por: Ma, Si-Cong, et al.
Publicado: (2021)

Immune Checkpoint Inhibitors for Advanced Melanoma: Experience at a Single Institution in Taiwan
por: Wu, Chiao-En, et al.
Publicado: (2020)

Immune Checkpoint Inhibitors in Advanced Acral Melanoma: A Systematic Review
por: Zheng, Qingyue, et al.
Publicado: (2020)

Biomarkers for Response of Melanoma Patients to Immune Checkpoint Inhibitors: A Systematic Review
por: Jessurun, Charissa A. C., et al.
Publicado: (2017)

The Efficacy and Safety of Immune Checkpoint Inhibitors in Patients With Cancer and Preexisting Autoimmune Disease
por: Tang, Hui, et al.
Publicado: (2021)

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
por: Wu, Mingrui, et al.
Publicado: (2022)

Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity
por: Sieber, Brendan, et al.
Publicado: (2022)

Radiotherapy plus immune checkpoint inhibitor in prostate cancer
por: Li, Tianjie, et al.
Publicado: (2023)

Efficacy of immune checkpoint inhibitors for in-transit melanoma
por: Nan Tie, Emilia, et al.
Publicado: (2020)

Neoadjuvant checkpoint inhibitor immunotherapy for resectable mucosal melanoma
por: Ho, Joel, et al.
Publicado: (2022)

PET/CT radiomics for prediction of hyperprogression in metastatic melanoma patients treated with immune checkpoint inhibitors
por: Gabryś, H. S., et al.
Publicado: (2022)

The Predictive Value of Tumor Mutation Burden on Efficacy of Immune Checkpoint Inhibitors in Cancers: A Systematic Review and Meta-Analysis
por: Wu, Yongfeng, et al.
Publicado: (2019)

Efficacy of immune checkpoint inhibitors in non-small cell lung cancer: A systematic review and meta-analysis
por: Yang, Fang, et al.
Publicado: (2022)

Risk factors for cardiovascular adverse events from immune checkpoint inhibitors
por: Luo, Lingli, et al.
Publicado: (2023)

Risk of Pneumonitis Associated With Immune Checkpoint Inhibitors in Melanoma: A Systematic Review and Network Meta-Analysis
por: Sun, You-Meng, et al.
Publicado: (2021)

Effects of Concomitant Antibiotics Use on Immune Checkpoint Inhibitor Efficacy in Cancer Patients
por: Jiang, Shuai, et al.
Publicado: (2022)

Chemotherapy reinforces anti-tumor immune response and enhances clinical efficacy of immune checkpoint inhibitors
por: Zhang, Lin, et al.
Publicado: (2022)

The Prognostic Value of ctDNA and bTMB on Immune Checkpoint Inhibitors in Human Cancer
por: Wei, Jiayan, et al.
Publicado: (2021)

Efficacy and Safety of Immune Checkpoint Blockades in the Treatment of Ocular Melanoma: A Systematic Review and Meta-Analysis
por: Zhao, Lu, et al.
Publicado: (2021)

Correction: Efficacy of immune checkpoint inhibitors for in-transit melanoma
Publicado: (2020)

Efficacy of immune checkpoint inhibitors in different types of melanoma
por: Rossi, Ernesto, et al.
Publicado: (2020)

HYDIN mutation status as a potential predictor of immune checkpoint inhibitor efficacy in melanoma
por: Li, Liu, et al.
Publicado: (2023)

Immune Checkpoint Inhibitors in the Treatment of HCC
por: Donisi, Clelia, et al.
Publicado: (2021)

Safety and Efficacy of Transarterial Chemoembolization Combined With Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Hepatocellular Carcinoma
por: Yang, Fei, et al.
Publicado: (2022)

Safety and Efficacy of Personalized Cancer Vaccines in Combination With Immune Checkpoint Inhibitors in Cancer Treatment
por: Liao, Juan-Yan, et al.
Publicado: (2021)

Growth hormone associated with treatment efficacy of immune checkpoint inhibitors in gastric cancer patients
por: Zhao, Yue, et al.
Publicado: (2022)

Association Between FSIP2 Mutation and an Improved Efficacy of Immune Checkpoint Inhibitors in Patients With Skin Cutaneous Melanoma
por: Ying, Haoxuan, et al.
Publicado: (2021)

Immune Checkpoint Inhibitor-induced Fanconi Syndrome
por: Farid, Saira, et al.
Publicado: (2020)

Clinical utility of tumour mutational burden on efficacy of immune checkpoint inhibitors in malignant solid tumours: protocol for a systematic review and meta-analysis
por: Xiang, Xuemei, et al.
Publicado: (2022)

Predicting Durable Responses to Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer Using a Multi-Feature Model
por: Wang, Lei, et al.
Publicado: (2022)

Immune checkpoint inhibitors in cervical cancer: Current status and research progress
por: Xie, Yunkai, et al.
Publicado: (2022)

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC
por: An, Fengxiao, et al.
Publicado: (2023)

An oxidative stress biomarkers predict prognosis in gastric cancer patients receiving immune checkpoint inhibitor
por: Deng, Guiming, et al.
Publicado: (2023)

Immune-Related Adverse Events Predict the Efficacy of Immune Checkpoint Inhibitors in Lung Cancer Patients: A Meta-Analysis
por: Wang, Donghui, et al.
Publicado: (2021)

Association Between Efficacy of Immune Checkpoint Inhibitors and Sex: An Updated Meta-Analysis on 21 Trials and 12,675 Non-Small Cell Lung Cancer Patients
por: Xue, Chongxiang, et al.
Publicado: (2021)

Outcome of immune checkpoint inhibitors in patients with extensive-stage small-cell lung cancer and brain metastases
por: Wang, Chunyu, et al.
Publicado: (2023)

Operative management of immune checkpoint colitis following in-transit melanoma: Case report
por: Childers, Betzaira G., et al.
Publicado: (2023)

Editorial: Immune checkpoint inhibitors in renal cell carcinoma
por: Tykodi, Scott S., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_jtm9ndek35spmndvde12tcv4pg